Last edition
News about "Seishi Katsumata"
Ono Pharma Enters into Drug Discovery Partnership with Aitia in Neurological Diseases
Ono Pharma partners with Aitia to use causal Artificial Intelligence (AI) and Gemini Digital Twins for novel drug target discovery in neurological diseases.
Seishi Katsumata | 03/09/2026 | By News Bureau
Ono Pharmaceutical Partners with Congruence Therapeutics for Neurology and Immunology Drug Discovery
Ono Pharmaceutical has expanded its collaboration with Congruence Therapeutics, leveraging the Revenir platform to discover small molecule modulators in neurology and immunology. Ono will hold exclusive worldwide option rights for development and commercialisation of resulting candidates.
Seishi Katsumata | 03/03/2026 | By Akanki | 210
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy